Clinical use

The clinical efficacy of glitinides is similar to that of the sulfonylureas. In short-term, placebo-controlled trials, repaglinide monotherapy reduced HbA1C levels from 8.5% at baseline to 7.8% after only 12 weeks. In individuals with T2DM not previously treated with other oral hypoglycemic agents, repaglinide resulted in a 30% decrease in HbA1C, from 6.9% to 4.8%, with fasting and postprandial blood glucose levels decreased by 70 and 112mgdL_ 1, respectively. Repaglinide59 and nateglinide60 as combination therapy with metformin are more effective than either agent alone. Glitinides are taken before every meal but are not taken if a meal is skipped.

Was this article helpful?

0 0
Diabetes Sustenance

Diabetes Sustenance

Get All The Support And Guidance You Need To Be A Success At Dealing With Diabetes The Healthy Way. This Book Is One Of The Most Valuable Resources In The World When It Comes To Learning How Nutritional Supplements Can Control Sugar Levels.

Get My Free Ebook


Post a comment